MA33534B1 - Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine - Google Patents

Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine

Info

Publication number
MA33534B1
MA33534B1 MA34641A MA34641A MA33534B1 MA 33534 B1 MA33534 B1 MA 33534B1 MA 34641 A MA34641 A MA 34641A MA 34641 A MA34641 A MA 34641A MA 33534 B1 MA33534 B1 MA 33534B1
Authority
MA
Morocco
Prior art keywords
human
antibodies
angiobots
high affinity
affinity against
Prior art date
Application number
MA34641A
Other languages
Arabic (ar)
English (en)
Inventor
Gavin Thurston
Christopher Daly
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33534(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA33534B1 publication Critical patent/MA33534B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES ANTICORPS QUI SE LIENT À L'ANGIOPOÏÉTINE 2 (ANG-2) ET DES MÉTHODES POUR LES UTILISER. SELON CERTAINS MODES DE RÉALISATION DE L'INVENTION, LES ANTICORPS SONT DES ANTICORPS TOTALEMENT HUMAINS QUI SE LIENT À L'ANG-2 HUMAINE. LES ANTICORPS DE L'INVENTION SONT UTILES, ENTRE AUTRES, POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À UNE OU PLUSIEURS DES ACTIVITÉS BIOLOGIQUES DE L'ANG-2 Y COMPRIS L'ANGIOGENÈSE.
MA34641A 2009-07-29 2012-02-16 Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine MA33534B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22941809P 2009-07-29 2009-07-29
US29519410P 2010-01-15 2010-01-15
PCT/US2010/043295 WO2011014469A1 (fr) 2009-07-29 2010-07-27 Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine

Publications (1)

Publication Number Publication Date
MA33534B1 true MA33534B1 (fr) 2012-08-01

Family

ID=42937802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34641A MA33534B1 (fr) 2009-07-29 2012-02-16 Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine

Country Status (40)

Country Link
US (4) US8987420B2 (fr)
EP (1) EP2459592B1 (fr)
JP (1) JP5701876B2 (fr)
KR (1) KR101781786B1 (fr)
CN (2) CN104258390B (fr)
AR (1) AR077333A1 (fr)
AU (1) AU2010276544B2 (fr)
BR (1) BR112012001984B8 (fr)
CA (1) CA2769334C (fr)
CL (1) CL2012000229A1 (fr)
CO (1) CO6491118A2 (fr)
CR (1) CR20120086A (fr)
CY (1) CY1117695T1 (fr)
DK (1) DK2459592T3 (fr)
EC (1) ECSP12011694A (fr)
ES (1) ES2582405T3 (fr)
HK (2) HK1166806A1 (fr)
HR (1) HRP20161043T1 (fr)
HU (1) HUE030508T2 (fr)
IL (1) IL217680A (fr)
JO (1) JO3182B1 (fr)
MA (1) MA33534B1 (fr)
ME (1) ME02484B (fr)
MX (1) MX2012001094A (fr)
MY (1) MY156816A (fr)
NI (1) NI201200014A (fr)
NZ (1) NZ598202A (fr)
PE (1) PE20121129A1 (fr)
PL (1) PL2459592T3 (fr)
PT (1) PT2459592T (fr)
RS (1) RS55054B1 (fr)
RU (1) RU2545399C2 (fr)
SG (1) SG178114A1 (fr)
SI (1) SI2459592T1 (fr)
SM (1) SMT201600251B (fr)
TN (1) TN2012000040A1 (fr)
TW (1) TWI527591B (fr)
UY (1) UY32812A (fr)
WO (1) WO2011014469A1 (fr)
ZA (1) ZA201200658B (fr)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (fr) 2003-05-30 2012-12-19 Merus B.V. Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
RS52036B (en) * 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
ES2689274T3 (es) 2008-01-03 2018-11-13 The Scripps Research Institute Dirección de anticuerpos mediante un dominio de reconocimiento modular
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
CA2712000A1 (fr) 2008-01-28 2009-08-06 Medimmune Limited Anticorps stabilises contre l'angiopoietine-2 et leurs utilisations
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
WO2012137993A1 (fr) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Anticorps dirigés contre les angiopoïétines 1 et 2, et leur utilisation
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
KR20140054303A (ko) 2011-08-19 2014-05-08 리제너론 파아마슈티컬스, 인크. 항-Ｔｉｅ２ 항체 및 이의 용도
JP2014533930A (ja) 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
EP2760471B9 (fr) 2011-09-30 2017-07-19 Dana-Farber Cancer Institute, Inc. Peptides thérapeutiques
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013112438A1 (fr) * 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Formulations stabilisées contenant des anticorps anti-ang2
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
HUE044263T2 (hu) * 2012-03-30 2019-10-28 Boehringer Ingelheim Int ANG2-kötõ molekulák
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
CN104768575B (zh) * 2012-08-31 2017-09-08 国立大学法人大阪大学 含有vegf特异性表位和/或血管生成素‑2特异性表位的dna疫苗
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AU2013322564A1 (en) * 2012-09-28 2015-03-12 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual Angiopoietin-2 / Dll4 binders and anti-VEGF agents
CA2883807A1 (fr) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Combinaisons pharmaceutiques comprenant des liants doubles angiopoietine-2/dll4 et des agents anti-vegf-r
WO2014078306A1 (fr) 2012-11-13 2014-05-22 Regeneron Pharmaceuticals, Inc. Anticorps anti-récepteur de prokinéticine (prokr) et leurs utilisations
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
EP3424530A1 (fr) 2013-03-15 2019-01-09 Zyngenia, Inc. Complexes multispécifiques monovalents et multivalents et leurs utilisations
US10745483B2 (en) 2013-03-15 2020-08-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US9663499B2 (en) 2013-06-07 2017-05-30 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
EP2835380B2 (fr) 2013-07-29 2021-04-07 Samsung Electronics Co., Ltd Procédé de blocage de fuite vasculaire utilisant un anticorps anti-ANG2
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
AU2014337135B2 (en) 2013-10-18 2019-09-19 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
CN105873599A (zh) * 2013-11-01 2016-08-17 瑞泽恩制药公司 用于治疗脑型疟疾的基于血管生成素的干预手段
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
US10279021B2 (en) 2014-03-14 2019-05-07 Dana-Faber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015256052A1 (en) * 2014-05-07 2016-11-10 Medimmune, Llc Methods of using anti-Ang2 antibodies
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
KR102349370B1 (ko) 2014-05-26 2022-01-10 삼성전자주식회사 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도
CA2964470A1 (fr) 2014-10-17 2016-04-21 Amgen Inc. Anticorps diriges contre l'angiopoietine 1 et l'angiopoietine 2 pour therapies oculaires
WO2016073157A1 (fr) * 2014-11-06 2016-05-12 Genentech, Inc. Anticorps anti-ang2 et procédés d'utilisation de ces anticorps
EP3699198A1 (fr) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Procédés pour le traitement de tumeurs à l'aide d'anticorps bispécifiques cd3xcd20
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
WO2016094570A1 (fr) 2014-12-10 2016-06-16 The California Institute For Biomedical Research Inhibiteurs de fibrose à petites molécules
WO2016115218A1 (fr) * 2015-01-14 2016-07-21 The California Institute For Biomedical Research Conjugués anticorps-médicament pour le traitement d'états immunitaires
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
EP3273998B1 (fr) 2015-03-27 2019-09-04 Regeneron Pharmaceuticals, Inc. Dérivés de maytansinoïde, conjugués de ceux-ci, et procédés d'utilisation
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MA42843A (fr) 2015-09-16 2018-07-25 Ablexis Llc Anticorps anti-cd115
ES2901133T3 (es) 2015-09-23 2022-03-21 Regeneron Pharma Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos
CA3007644A1 (fr) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methodes pour ralentir ou empecher la croissance de tumeurs resistantes au blocage de l'egfr et/ou d'erbb3
CN108366968B (zh) 2015-12-16 2022-02-18 瑞泽恩制药公司 制造蛋白质微粒的组合物和方法
MA43094B1 (fr) 2016-01-25 2020-10-28 Regeneron Pharma Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation
MX2018009011A (es) 2016-02-02 2018-11-19 Hutchinson Fred Cancer Res Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途
CA3031542A1 (fr) 2016-07-20 2018-01-25 University Of Utah Research Foundation Lymphocytes car-t cd229 et leurs procedes d'utilisation
CA3037732A1 (fr) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anticorps anti-steap2, conjugues anticorps-medicament, et molecules bispecifiques de liaison a l'antigene qui se lient a steap2 et cd3, et leurs utilisations
RS63660B1 (sr) 2016-09-23 2022-11-30 Regeneron Pharma Anti-muc16 (mucin 16) antitela
US11352425B2 (en) 2016-11-08 2022-06-07 Absos, Llc Anti-CD47 antibodies
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
KR20190091290A (ko) 2016-11-29 2019-08-05 리제너론 파아마슈티컬스, 인크. Ｐｒｌｒ 양성 유방암 치료 방법
WO2018114728A1 (fr) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
CN110709104A (zh) 2017-05-06 2020-01-17 瑞泽恩制药公司 用aplnr拮抗剂和vegf抑制剂治疗眼部病症的方法
US11434303B2 (en) 2017-06-28 2022-09-06 Bluefin Biomedicine, Inc. Anti-LY6H antibodies and antibody drug conjugates
CN110662771B (zh) * 2018-02-01 2023-07-28 南京驯鹿生物技术股份有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
KR102497171B1 (ko) * 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
EP3774866A1 (fr) 2018-04-13 2021-02-17 Ludwig Institute for Cancer Research Ltd Récepteurs d'antigènes chimériques inactivables hétérodimères
JP7328990B2 (ja) 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
WO2019235856A1 (fr) 2018-06-07 2019-12-12 기초과학연구원 Anticorps se liant à tie2 et son utilisation
CA3101506A1 (fr) 2018-06-07 2019-12-12 Institute For Basic Science Anticorps se liant a tie2 et son utilisation
US20220040319A1 (en) 2019-02-21 2022-02-10 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
AU2020227580A1 (en) * 2019-02-25 2021-09-30 Pharmabcine Inc. Anti-Ang2 antibody and use thereof
WO2020232243A2 (fr) * 2019-05-14 2020-11-19 Froude Jeffrey W Anticorps contre le virus ebola et soudan
EP3982997A4 (fr) * 2019-06-14 2023-09-13 Dana-Farber Cancer Institute, Inc. Anticorps dirigés contre pdl1 et procédés d'utilisation associés
WO2020257681A1 (fr) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Utilisation de molécules de liaison à l'antigène bispécifiques se liant à psma et cd3 en combinaison avec une co-stimulation de 4-1bb
JP2022537269A (ja) 2019-06-21 2022-08-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
US20230141511A1 (en) 2019-12-20 2023-05-11 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
IL295312A (en) 2020-02-28 2022-10-01 Regeneron Pharma Bispecific antigen binding molecules that bind her2 and methods of using them
IL296043A (en) 2020-03-06 2022-10-01 Regeneron Pharma Anti-gitro antibodies and their uses
WO2021226444A2 (fr) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Pièges et mini-pièges de vegf et procédés de traitement de troubles oculaires et de cancers
WO2022015656A1 (fr) 2020-07-13 2022-01-20 Regeneron Pharmaceuticals, Inc. Analogues de camptothécine conjugués à un résidu de glutamine dans une protéine et leur utilisation
WO2022031882A1 (fr) * 2020-08-06 2022-02-10 Stelexis Therapeutics, Llc Anticorps anti-il-8 et méthodes d'utilisation associées
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
KR20230084507A (ko) * 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도
CA3190569A1 (fr) 2020-10-22 2022-04-28 Christopher Daly Anticorps anti-fgfr2 et leurs methodes d'utilisation
KR20230107261A (ko) 2020-11-10 2023-07-14 리제너론 파마슈티칼스 인코포레이티드 셀레늄 항체 접합물
WO2022159875A1 (fr) 2021-01-25 2022-07-28 Regeneron Pharmaceuticals, Inc. Anticorps anti-pdgf-b et procédés d'utilisation pour le traitement de l'hypertension artérielle pulmonaire (pah)
KR20240024061A (ko) 2021-06-22 2024-02-23 리제너론 파마슈티칼스 인코포레이티드 항-EGFRvIII 항체 약물 접합체 및 이의 용도
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
WO2023196903A1 (fr) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Molécules bispécifiques de liaison à l'antigène qui se lient et cd3 et antigènes associés à une tumeur (taa) et leurs utilisations
TWI833641B (zh) 2022-05-02 2024-02-21 丹麥商諾佛 儂迪克股份有限公司 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體
WO2023240109A1 (fr) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Molécules multispécifiques pour moduler l'activité des lymphocytes t, et leurs utilisations
WO2024118785A2 (fr) 2022-11-30 2024-06-06 Regeneron Pharmaceuticals, Inc. Agonistes de tlr7 et conjugués anticorps-médicament associés
CN116003591B (zh) * 2022-12-12 2023-09-19 三门峡市眼科医院 Ang-2抗体及其应用
US20240269308A1 (en) 2022-12-21 2024-08-15 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
CN116789813B (zh) * 2023-06-27 2024-04-26 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌α-溶血素的单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2519875C (fr) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Methode favorisant la regression de tumeurs au moyen d'inhibiteurs du vegf (facteur de croissance de l'endothelium vasculaire)
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
RS52036B (en) 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
EP1853294A4 (fr) 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd Composés antiangiogéniques
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
CN101370519B (zh) 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CA2712000A1 (fr) 2008-01-28 2009-08-06 Medimmune Limited Anticorps stabilises contre l'angiopoietine-2 et leurs utilisations
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CA2761233A1 (fr) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Anticorps tri- ou tetraspecifiques
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
US20110027286A1 (en) 2011-02-03
HK1166806A1 (zh) 2012-11-09
DK2459592T3 (en) 2016-08-29
CA2769334C (fr) 2018-06-12
UY32812A (es) 2011-04-29
US10875911B2 (en) 2020-12-29
MX2012001094A (es) 2012-03-14
NI201200014A (es) 2012-05-29
ES2582405T3 (es) 2016-09-12
CO6491118A2 (es) 2012-07-31
CY1117695T1 (el) 2017-05-17
US9938339B2 (en) 2018-04-10
EP2459592A1 (fr) 2012-06-06
TW201116296A (en) 2011-05-16
PE20121129A1 (es) 2012-09-04
BR112012001984B8 (pt) 2021-05-25
CL2012000229A1 (es) 2012-10-05
RU2012107286A (ru) 2013-09-10
JO3182B1 (ar) 2018-03-08
US8987420B2 (en) 2015-03-24
KR20120087891A (ko) 2012-08-07
KR101781786B1 (ko) 2017-09-26
HK1205470A1 (en) 2015-12-18
SI2459592T1 (sl) 2016-07-29
AU2010276544B2 (en) 2014-03-27
CN102549015A (zh) 2012-07-04
AU2010276544A1 (en) 2012-03-01
WO2011014469A1 (fr) 2011-02-03
ME02484B (fr) 2017-02-20
SG178114A1 (en) 2012-03-29
ZA201200658B (en) 2012-10-31
NZ598202A (en) 2013-12-20
PT2459592T (pt) 2016-08-17
TN2012000040A1 (en) 2013-09-19
EP2459592B1 (fr) 2016-05-18
HRP20161043T1 (hr) 2016-10-21
US20210101969A1 (en) 2021-04-08
RS55054B1 (sr) 2016-12-30
BR112012001984B1 (pt) 2020-10-27
CR20120086A (es) 2012-06-01
CN104258390A (zh) 2015-01-07
CN104258390B (zh) 2017-09-08
RU2545399C2 (ru) 2015-03-27
SMT201600251B (it) 2016-08-31
CN102549015B (zh) 2014-10-15
US20150152177A1 (en) 2015-06-04
TWI527591B (zh) 2016-04-01
MY156816A (en) 2016-03-31
PL2459592T3 (pl) 2016-11-30
IL217680A (en) 2016-04-21
ECSP12011694A (es) 2012-04-30
US20180186869A1 (en) 2018-07-05
CA2769334A1 (fr) 2011-02-03
HUE030508T2 (en) 2017-05-29
JP2013500970A (ja) 2013-01-10
AR077333A1 (es) 2011-08-17
JP5701876B2 (ja) 2015-04-15

Similar Documents

Publication Publication Date Title
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
MA37945A1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées
MY165273A (en) Anti-cd48 antibodies and uses thereof
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
FR2938437B1 (fr) Utilisation cosmetique de microorganisme pour le traitement des peaux grasses
JO3246B1 (ar) اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA31767B1 (fr) Composes organiques et leurs utilisations
MA31838B1 (fr) Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations
MA32654B1 (fr) Composés modulant sélectivement le récepteur cb2
TN2010000068A1 (en) Anticorps anti-cd37
MA34277B1 (fr) Pyrrolobenzodiazépines et conjugués de celles-ci
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MA47221A1 (fr) Anticorps monoclonal à pd-l1
TW200603828A (en) Treatment of disorders
MA38478A1 (fr) Anticorps anti-pac1 humains
MA33155B1 (fr) Composes organiques et leurs utilisations
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations